Monday, October 3, 2022


Biotechnology News Magazine

Boston Immune Technologies and Therapeutics Raises $10M Series A Financing

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 17, 2021

Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel TNF Superfamily antagonist antibodies, announced today that the company has completed $10 M Series A/A1 preferred stock financing.

Investors in the Series A preferred stock financing include BeiGene, Ltd., along with undisclosed private investors and prior investors Hatteras Venture Partners and EGP Investments.

The funds will support the clinical development of BIR2101, a novel, TNFR2 antagonist antibody for indications in oncology and infectious disease and additional pipeline candidates. The company also announced that Lusong Luo, Ph.D., Senior Vice President of External Innovation at BeiGene, and Joseph McMahon, CEO of Bioventure Partners, will be joining BITT’s board of directors.

Boston Immune Technologies and Therapeutics, Russell LaMontagne, Co-founder and Chief Executive Officer“This funding, in combination with our recent option and license arrangement with BeiGene, means BITT has the resources to move BIR2101 into the clinic and support proof of concept studies for additional TNF Superfamily targets,” said Russell LaMontagne, Co-founder and Chief Executive Officer of BITT.

BITT is exploring clinical trials for BIR2101 as monotherapy and in combination with checkpoint blockade. TNFR2 is highly expressed on the most suppressive cells in the tumor microenvironment and has been identified as a driver of resistance to checkpoint blockade. In multiple murine models, the combination of TNFR2 with PD-1 results in significantly higher cure rates. BITT anticipates filing an IND for BIR2101 by end of 2021. Discovery stage antagonist antibodies for additional TNF Superfamily targets are in development.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine